drugset / Trial / NCT01356160
GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy with GS-5885 Alone or in Combination with GS-9451 with Peginterferon Alfa 2a and Ribavirin in Treatment Naïve Subjects with Chronic Genotype 1 Hepatitis C Virus Infection.
Timeline
- Start
- 2011-07
- Primary completion
- 2013-06
- Completion
- 2013-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | vedroprevir | Small molecule | 200 mg | — |
| Comparator | Ledipasvir | Small molecule | 30 mg | — |
| Comparator | Peginterferon alfa-2a | Protein / enzyme biologic | 180 ug | Other |
| Comparator | ribavirin tablet | Unknown | 1000 mg | — |
| Comparator | ribavirin tablet | Unknown | 1200 mg | — |